Horien Biotech (7814) officially listed on the OTC market on the 16th at NT$28.45 per share. The stock price reached NT$32.15 in early trading, a 13.01% increase, initiating a honeymoon period. Horien Biotech Chairman Tsai Kuo-Tien stated that the company will further deepen its global market penetration by leveraging top-tier medical-grade raw materials and groundbreaking high-end medical devices, building upon its existing dental and surgical channels. This is driven by the acquisition of international certifications and the harvesting of innovative product lines.

 Horien Biotech, with its strong R&D capabilities and deep technological barriers, has recently delivered outstanding results in revenue performance, international certifications, global market layout, and the implementation of a top-tier biomedical raw material supply chain. This demonstrates the powerful momentum of its dual-engine strategy of "deepening existing medical device development and developing high-end innovative medical devices," attracting significant attention from the capital market.

 Driven by continued strong demand in the US, Taiwan, and overseas markets, Horien Biotech achieved a remarkable 209.29% revenue growth in June, marking a successful start to its OTC listing. Beyond its strong fundamentals, Horien Biotech has made significant progress in expanding its overseas presence.

 On July 7th, Horien Biotech successfully obtained three high-risk (Class 4, highest level) medical device market access licenses in Thailand, gaining a foothold in the ASEAN high-end medical device market. Furthermore, it is expected to obtain Class III medical device licenses in the Philippines and Vietnam soon, signifying that its strategic layout in the Southeast Asian market is nearing completion.

 Moreover, the company's highly anticipated bio-ink innovative product is planned for export to the European market by the end of this year, extending its international footprint from Asia to Europe and America, and anticipating a surge in global revenue contributions.

 In the research and development of high-end innovative medical devices, Horien Biotech has achieved a disruptive world-class breakthrough. Its independently developed "biodegradable ureteral stent" has successfully obtained a Taiwanese invention patent and is expected to soon secure invention patents in the United States, Europe, and China.

Currently, this innovative product has successfully completed sample development and has been officially delivered for animal testing. As no international competitors have yet obtained the relevant medical device certifications, Horien Biotechnology is at the forefront globally. This product not only addresses the clinical pain point of traditional stents requiring secondary surgery for removal, but also targets a pristine blue ocean market worth billions of US dollars with no competition.

 Simultaneously, collagen regeneration patches developed using the core "advanced decellularization technology," primarily for surgical and orthopedic tissue repair, have recently entered the trial production stage, providing a strong profit foundation for the medium- to long-term product line.

 To meet the explosive global demand and ensure a secure supply of high-end medical device raw materials, Horien Biotechnology's subsidiary, Shengli Biotechnology Co., Ltd., has officially signed a Memorandum of Understanding (MOU) and cooperation agreement with Taiwan Sugar Corporation and Taiwan Livestock Products Import & Export Corporation, complying with ISO 13485 (Medical Device Quality Management System) and ISO 22442 (Risk Management of Medical Devices Using Animal Tissue).

 This move not only established a medical-grade animal-derived raw material supply chain with international high standards, but also broke the long-standing monopoly of international biomedical giants at its root, leading Taiwan's traditional animal husbandry industry to successfully transform into a top-tier biomedical field with added value of hundreds of times.

Report Link:

Horien Biotech's listing on the OTC market and its expansion into ASEAN and Europe bring good news; a multi-billion dollar blue ocean medical device market is poised for growth.

UDN.COM / Xie Bai-Hong